| Related sites for http://www.prohostonline.com/ |
| Perfect_Time_Systems Distributor of Isgus time recorders. United States. | | Franchise_Architects Management consulting firm specializing in the design of custom development and expansion programs. Testimonials and contact form provided. | | Adams_Healthcare,_Ltd_ Manufacture and marketing of pharmaceutical and contamination control products. Supply of surgical instruments and medical equipment to healthcare sector. | | VCA_Antech Owns and operates veterinary hospitals and veterinary clinical laboratories and markets and distributes premium and therapeutic pet foods. (Nasdaq: VCAI). | | Ultimate_Duvet_Co Canada. Design and manufacture of hand sewn, goose feather and down filled quilts and pillows, with cotton ticking fabrics. Size charts and technical information. Links to related sites. | | Circa_Music Hear and see audio and video samples, read about us, pictures of our facility and contact information. | | Columbia_Fire_and_Safety,_Ltd_ Distributes personal protective equipment, fire protection products and first aid kits. | | Design_X_Manufacturing_Inc Suppliers of salon equipment including styling chairs and stations, reception desks, manicure tables, hair dryers, pedicure stations, spa equipment and mirrors. | | ITC_Holland Offers used equipment from Europe delivered anywere in any condition direct to the end-users by the company's exclusive ITC partners. | | Teasdale_Quality_Foods Producers of a variety of canned bean and hominy products. Company profile, product information, recipes, and contact details. | | XiangYun_Technology_Pte_Ltd Raw materials supply to steel mills world-wide. Supplier of iron ore, scrap metal, non-ferrous scrap, steel billets, coking coal to steel mills world wide. Site in English and Chinese. | | Twenty_Something,_Inc_ Services include strategic planning and marketing research. | | Texcel Supplies process and industrial controls including pressure, temperature, flow and level switches. Flow meters, level measurement, non return valves and pinch valves. | | David_Electronics_Company_Ltd_ Manufacturer of power cords, computer connectors and accessories. | | Bosch_Appliances Manufactures dishwashers, cook tops, ovens, and washers and dryers in North America. | | The_World_of_Engineered_Wood Home page of the Composite Panel Association and the Composite Wood Council, representing the particleboard and medium density fiberboard (MDF) industries, and related products. | | Orton_Engineering Manufacturer of vibrating feeders, screens, furnace chargers, unbalanced vibratory motors, motorized cable reeling drums, spring operated cable reeling drums, cable drag chains, resistance boxes. | | Termoaparatura_Wroclaw Polish company offers the manufacturer of industrial temperature sensors. | | Mike_Redwood UK. Consultant to the leather and associated industries, specialised in marketing strategies, technology management and innovation. Library of articles. Time line and history of leather tanning. Gloss | | Designer_Fabrics_Online On-line sales of designer upholstery and furnishing fabrics. Detailed fabric catalogs, providing fabric specifications and prices. |
|
Prohost Biotechnology
Prohost Biotechnology Online
The Newsletter of Biotechnology Research and Investment
   
To
Subscribe Click
Subscribe now!!!.
SEPT 9,2008
PROHOST
 FILTER
TYSABRI FOR CANCER, AND MORE
09/05/2008 Tysabri is a great drug. Not only
it amazes neurologists and gastroenterologists about its superior effect
on M.S. and Crohn\'s disease patients, the drug might be on its way to
amaze oncologists. In another unrelated subject, a novel monoclonal
antibody targeting a protein involved in autoimmune disease might offer
hope for patients suffering from systemic lupus erythematosus.
NEW TREATMENTS FOR UNTREATED DISEAS....
09/04/2008 Deep vein thrombosis,
thromboembolisms, hereditary antithrombin deficiency and Alzheimer\'s
disease.
TWO BIOTECHS CASHED MILESTONE PAYME....
09/02/2008 Collaboration between biotech and
pharmaceutical firms begins with the interest of big pharma in
breakthrough molecules developed by biotech firms. An early signal of
success is receiving a deserved milestone payment from collaborators. The
comforting signal has come from two development stage biotech firms.
AMGEN: A NEW HOPE FOR PATIENTS OFFE....
08/25/2008 Could it be that investors might
not like to see the patients who spend their lives in fear of bleeding get
rid of that fear? (For subscribers only.)
OUR OPINION WILL NOT STOP THEM FROM....
08/22/2008 The is a large difference between
positive and negative views and opinions in their ability to impact
stocks. Three biotech companies have lost most of their values based on
negative views. Now, we are witnessing determination by negative assessors
to bring down another biotech firm.
PDL BIOPHARMA AGREEMENT WITH BRISTOL MEYRS:
.08/20/2008 Elotuzumab offers a
new approach for the treatment of multiple Myeloma. It attracted
Bristol-Myers Squibb and the agreement is signed. The drug is in early
phase trial, but (for subscribers only)
EYE BLINDNESS, HEART DISEASE AND AI....
08/19/2008 The goal of the sound
professional biotech firms is to provide far-reaching treatments. Here we
witness a successful outcome of a breakthrough treatment for wet macular
degeneration, another for a hereditary heart condition known as long QT
syndrome (LQT3) and a serious attempt by a top of the world institute,
Karolinska Institute, to use an adjuvant developed by VICAL to test an HIV
vaccine.
TWO DRUGS REACHED THE END OF THE TH....
08/18/2008 Two drugs developed by two small
biotech firms have reached the end of the road towards approval. The first
is for head and neck cancer; the second is for hereditary angioedema (HAE)
XENAPINE APPROVED FOR HUNTINGTON\'....
08/18/2008 The FDA has cleared the first
treatment for Huntington\'s\" disease, which affects approximately
\"30,000 pa-tients in the United States. Xenazine (tetrabenazine), treats
chorea, the involuntary movement that occurs in patients with the disease.
MICROMET (MITI) AND NON-HODGKIN\'S: .08/15/2008
Blinatumomab Phase 1 trial on non-Hodgkin\'s lymphoma regressed
tumors in patients who relapsed after previous treatments and were
considered to have incurable disease.
ATRYN: CLOSING THE COLLABORATION AG....
08/15/2008 The agreement brings in $257
million in potential payments t for meeting clinical, regulatory, and
sales milestones,
GILEAD: ANOTHER HBV DRUG APPROVAL
08/12/2008 Gilead\'s drug Viread is approved
for HBV. Epix\' (EPIX) novel molecules for chronic obstructive pulmonary
disease (COPD) and moderate-to-severe pulmonary hypertension (PH). Icahn
is buying m
EYE ON: GENZ; HDVY; CRME
08/07/2008 A promising drug for Heterozygous
familial hypercholesterolemia (heFH). A more accurate test for prostate
cancer by a tiny biotechnology firm, Expecting FDA answer for Cardiome\'s
atrial fibrillation drug. Next Saturday, read about how MODIGENE (MODG.OB)
has indirectly validated its unique long acting drug delivery technology.
We were waiting for this validation.
EYE ON: ALNYLAM
08/06/2008 More validation for Alnylam\'s RNAi technology and
programs.
EYE ON: MEDX, CLDA
08/05/2008 The FDA gave the green
light for Medarex drug MDX-1105 to begin clinical trials. Clinical Data
acquires Adenosine Therapeutics, L.L.C.
TYSABRI: TIME TO KNOW THE TRUTH
08/04/2008 The time has come for people to
know that other drugs are also associated with PML, that PML is related to
diseases and that it is an extremely rare side effect.
EYE ON: DRUGS' SIDE EFFECTS?
08/01/2008 From as many as 31,800 M.S.
patients who took Tysabri, only two developed symptoms of cerebral
infection. No deaths have been reported and no cases of infection in the
U.S. Many other best selling drugs have the same side effects.
EYE ON ELAN
07/30/2008 They should have known better those who are printing the
wrong stuff. The sell-off began before, not after the conference call. We
predicted it. The drug is promising.
EYE ON: BAPINEUZUMAB
07/29/2008 Today, Bapineuzumab will be
discussed, especially Phase 2 trials. The major topic, though, we believe,
will be a large subgroup of patients who can be pinpointed who benefited
from the drug.
AMGEN IS THE STAR OF BIOTECHNOLOGY
07/28/2008 we will not be surprised to see
AMGN rally. As we kept telling you, the star will continue to prove it is
the star of the biotech industry. All the bad that has been said about
this firm has not, and will not affect its outperformance. Suddenly many
are seeing how heavyweight Amgen is, and how it is and will continue to be
an outperformer. The reason for the enthusiasm? Its osteoporosis drug
Desonumab.
GENENTECH AGAIN
07/15/2008 As we expected, by raising their
expectations, analysts got what they wanted from investors who believe in
the meeting analysts expectations irrational, or irrationally used rule
of thumb. The rule is crazy because by just raising their expectations,
the masters are directly and indirectly expressing their conviction that
the firm has a strong showing; strong sales and strong plans.
GENENTECH AND OTHER NEWS
07/14/2008 Fairness in the stock
market is a slow process that takes time to apply. The only act of common
sense in the market is to follow history, which clearly tells us that good
news can be easily turned into bad news.
SOME NEWS
06/30/2008
HE SAID, SHE SAID, THEY SAID
06/27/2008 You will always hear a lot of
opposing and challenging opinions, not only on Vandas sleeping pill
tasimelteon, but on each and every drug following the announcement of
results from clinical trials. The truth is ..
GOOD NEWS IN A BAD MARKET
06/26/2008 Another bad market day, which
makes us expect some profit taking from the firms that have been recently
in rallying moods. There is good news, but the bad bear will not let their
news boost their stocks. The good news, though, must be remembered for
future consideration.
WHAT'S NEW FOR TYPE 1 DIABETES
06/25/2008 Developing a treatment
that could halt progression of type 1 diabetes and preserve enough islet
cell function to avoid the need for insulin administration all together is
the ultimate goal of endocrinologists.
BIOTECHNOLOGY IN A SLIDING MARKET
06/24/2008 In the bad market,
the biotechnology sector is looking solid compared to other industrial
sectors, big and small.
CONTROLLING GENES
06/19/2008 Three years and two
months of testing Sangamo\'s technology were sufficient to validate its
capability to manipulate genes and revolutionize agriculture, fuel and
drug industries.
TECHNOLOGIES
AND THE BIOREVOLUTION 06/17/2008
Some biotechnology firms look sometimes like faltering with no
remedy to revive them. All of a sudden, news that looks of little impact
might mark the beginning of resurrection.
IDENIX'
(IDIX) PROMISING HIV DRUG
06/12/2008 A novel HIV non-nucleoside reverse transcriptase
inhibitor drug has good results.
SANGAMO
(SGMO): PROMISING DATA IN D....
06/10/2008 At the 68th Scientific Sessions of the American Diabetes
Association (ADA), positive data were presented about Sangamo\'s ZFP
Therapeutic program. The presentation is entitled, \"Evidence of
Neuroregeneration Using Vascular Endothelial Growth Factor (VEGF) Zinc
Finger Protein Activator (SB-509) in Diabetic Neuropathy: A Chronic
Degenerative Polyneuropathy,\" Sangamo\'s Phase 1b results from clinical
trial (SB-509-401) demonstrated statistically significant improvements in
measurements of nerve health and function in subjects with diabetic
neuropathy.
SEQUENOM'S DOWN SYNDROME TEST
06/04/2008 Sequenom (SQNM), one of
Prohosts picks announced that its prenatal SEQureDX test, which screens
maternal blood for Down syndrome had a 100% success in predicting positive
disease. The stock rallied.
ALNYLAM (ALNY): BIG MONEY
05/27/2008 Another deep-pocketed
Japanese company, Takeda is attracted to Alnylam\'s RNAi technology.
HUMAN
PAPILLOMA VIRUS (HPV)
05/20/2008 A more accurate test for
HPV might save more women from developing cervical cancers.
ASCO: Too early to call
05/19/2008 Giving everybody access to
thousands of abstracts presented at ASCO is a step forward. The question
is: Will the unprecedented move by ASCO succeed in eliminating some
analysts rush to evaluate cancer drugs prior to the meeting, thus causing
confusion?
LPATH (LPTH): WHAT DID WE LEARN?
05/15/2008 What should we
learn from a press release? Taking as an example the news announced by
Lpath, we learned that the firm has the fundamentals indispensable for a
development-stage biotechnology company. These fundamentals are usually
overlooked by analysts, a leading cause for the undervaluation of many
biotechnology firms.
BIOTECHNOLOGY EVOLUTION IS BREATH-T....05/14/2008 Biotechnology is,
indeed, evolving with astonishing high speed towards unveiling the bodys
biological molecules involved in providing health, or causing diseases. We
have news here. (for subscribers only)
PROHOST E-LETTER #271
05/06/2008 For Subscribers Only.
Please click on the link on the Home page below.
WHAT HAPPENNED ON MARCH 28 IN A CHI....
05/02/2008 A child suffering from
Acute Lymphoblastic Leukemia (ALL), a cancer of the bone marrow and blood
has been treated by transplanting human placenta-derived stem cells (HPDSCs.
Read about the firm and the hospitals behind the groundbreaking transplant
IDERAS TOLL-LIKE RECEPTORS
05/01/2008 The Promises of TLR
technology
ZYMOGENETICS M.S. DRUG ATACICEPT
04/30/2008 Why atacicept for
M.S.
REGENERON: TOWARDS ANOTHER FINISH L....
04/28/2008
PROGENICS' DRUG APPROVAL
04/25/2008 Prohost warrned investors
that slashing Progenics stock price was irrelevant and the subcutaneous
form of methylnaltrexone will be approved. It was.
ELAN AND TYSABRI
04/24/2008 Hype has a short life span
because, sooner, or later, reality surfaces. Tysabri is one of the most
deliberately misjudged, if not the most underestimated breakthrough drugs
...
MIGRAINE
04/16/2008 The medical community has
become increasingly aware that Inflammation might be playing an important
role in many chronic and life-threatening diseases, including cancer.
Capitalizing on this notion, Pozen and GlaxoSmithKline added an
anti-inflammatory drug to a member of migraine-specific medicines. It
worked. The firms were granted FDA approval for a new better acting
migraine drug called Treximet.
PROMISING CANCER DRUGS
04/15/2008 Cancer drugs, Vaccines,
predictive tests and other presentations. (Subscribers only)
MILLENNIUM: A TAKE OVER
04/10/2008 Knowing better than
investors the value of Millennium Pharmaceuticals (MLNM), Takeda
Pharmaceutical Co. has bid $8.8 billion on Millennium. Stock has crossed
our $24 target.
ONCOPHAGE (VITESPEN) VACCINE APPRO....
04/08/2008 the Russian Ministry of
Public Health has issued a registration certificate for the use of
Oncophage (vitespen) developed by Antigenics (AGEN) for the treatment of
kidney cancer patients at intermediate risk for disease recurrence. The
company expects to launch Oncophage in Russia in the second half of 2008.
SANGAMO BIOSCIENCES (SGMO)
04/07/2008 More and more
scientists and drug developing firms, private and public, are becoming
aware that Sangamos ZFP Nuclease (ZFN) platform might be the breakthrough
that addresses many of the major problems hampering the success of
biological science revolution.
VERTEX' DRUG FOR CYSTIC FIBROSIS
04/01/2008 Vertex Announces Positive
Results for VX-770 - an oral Investigational Agent That Targets a
defective protein responsible for cystic fibrosis
COMPUGEN: A MARKER IN MYOCARDIAL IN....
04/01/2008 Compugen has provided the
medical community with what confirms the value of its predictive discovery
platforms. This capability has begun to bring in new valuable molecules,
which were not previously known.
A NEW DRUG TO DIMINISH HIV RESISTAN....
03/31/2008 A broad-spectrum antiviral
product candidate might suppress HIV resistance to nucleoside reverse
transcriptase inhibitors (NRTIs)
PRADAXA: A NOVEL ANTICOAGULANT
03/28/2008 Pradaxa, an oral direct
thrombin inhibitor. The novel drug is approved in Europe to prevent venous
thromboembolic events in adults who have undergone elective total hip or
total knee replacement surgery.
THE PROHOST N-LETTER IS POSTED
03/27/2008 The Game. The biotech
sector . The bad patterns. The rule of thumb and the biotech disciplines
that will supervene. (FOR SUBSCRIBERS ONLY>)
DINAVAX (DVAX) AND MERCK
03/18/2008 While receiving an
investigational hepatitis B vaccine, one individual among 2500 vaccinated
with 5000 doses of the HEPLISAV vaccine co-developed by Dynavax and Merck
was diagnosed with Wegener\'s granulomatosis,
GENTA'S DRUG GENASENSE
03/17/2008 Genta\'s drug, Genasense
inhibits Bcl-2, a protein that makes cancer resist chemotherapy.
GENENTECH'S YEAR AND YEARS
03/14/2008 It is, indeed, Genentechs
day, where the firm is expected to project 2008 profit outlook between
$3.30 and $3.45 per share, its Avastin\'s unprecedented sales growth, its
pipeline and its plans for the future.
PDL BIOPHARMACEUTICALS
03/05/2008 \"To sell ourselves, or
not to sell ourselves\", this is the question. \"We want to sell, but we
could not sell\", this is the cause of investors\' catastrophic losses.
The story repeats itself with different star players. Is it time to buy
now, or to think about it? What other biotechnology made us decide to buy
without thinking? Read the answer in the upcoming Prohost letter.
REWRITING THE TEXT BOOKS?
03/03/2008 The market first. Then
news from Vanda (VNDA) which insinuates that as a developer of
antipsychotic and neurological products, especially of an antipsychotic
drug waiting for approval, this firm is doing its homework.
GENENTECH: THE GIANT SUPERVENED
02/22/2008 We said it on
February 15. It happened on February 22. The FDA granted Avastin
accelerated approval to protect women from breast cancer spread and
protect investors from the market's parasites.
ONYX (ONXX) A BUY OPPORTUNITY
02/19/2008 The irrational selling of
the stock offers an opportunity for those who had missed buying the stock
and another opportunity to accumulate by the firms fans.
ADVANCED PROSTATE CANCER: A NEW HOP....
02/16/2008 A private biotech and a
publicly traded biotech firm might have good news for hormone refractory
prostate cancer. For subscribers only.
CORRECTING HYPONATREMIA
02/16/2008
PROHOST NEWSLETTER
For
Subscribers Only
PROHOST TABLE
For Issue #125 Part 2
PROHOST N-LETTER #125 PART TWO
PROHOST N-LETTER #125
ASCO
PROHOST N-LETTER #124
PROHOST E-LETTER
For
Subscribers Only
PROHOST E-LETTER #273
PROHOST E-LETTER # 272
PROHOST E-LETTER # 271
The best in
each Biotechnology discipline
ARCHIVE
JANUARY 2008
UPGRADES/DOWNGRADES
01/31/2008 Come to Predictive
medicine symposium.
It is open to the public.
EPIX: AND SEQUENOM:
01/24/2008 Epix Accomplishment for
Cystic Fibrosis.
Sequenom\'s prenatal Down Syndrome screening
DURING THE MARKET TURBULENCE
01/23/2008 Some are afraid and
others take
advantage. Where else to go?
FOR A FEW DOLLARS
01/10/2008 For Illumina, the
whole headache that was made
to look like a hurricane threatening the firm\'s existence is erased with
a low dose of pain
killer - $90 million only.
ISIS
AND ANTISENSE REVIVAL
01/08/2008
OSI (OSIP) AND OSIRIS (OSIR)
01/04/2008 Investors might have
finally decided
to appreciate the value of the technologies and products.
DECEMBER 2007
COMPUGEN: PERSONALIZED MEDICINE = P....
12/20/2007 Seeing is believing.
CompuGen signs a collaborative agreement with Roche
IDERA: A COLLABORATION AGREEMENT
12/19/2007 Idera signed a
collaboration
agreement with Merck KGaA.
SIMPLIFYING HIV-1 TREATMENT
12/18/2007 The European
Commission has granted
approval for Atripla, which combines Gilead
Sciences drugs Emtriva and Viread
with Bristol-Myers Squibbs Sustiva .
Also, Medarex Cashes in on Good News.
BIOGEN
IDEC: PROHOST EXPECTED MOVE
12/13/2007 The same reasons for BIIB's
failure to find
a buyer were there when the firm announced it accepted to be sold. We
cited them then,
others are mentioning them after the fact.
MORNING NEWS AND COMMENTS
12/07/2007 Good news for Medarex.
What about
Genentech?
GENENTECH'S AVASTIN
12/05/2007 Will Avastin Be
Recommended? Please don\'t
drive yourself crazy, or, may be better if you do.
NOVEMBER 2007
REGENERON IS ONE OF TEN
INTROGEN'S ADVEXIN
HAPPY THANKSGIVING
PHARMION:
ACQUISITION. NEXAVAR AP....
PFIZER TO ACQUIRE COLEY (COLY)
MILLENNIUM
PHARMACEUTICAL (MLNM)
SMOKE, MIRRORS AND DISTORTION
MLNM, VNDA, DVAX
LOU GEHRIG'S DISEASE
OCTOBER 2007
NEXAVAR: APPROVED IN EUROPE FOR LI....
SANGAMO: A FUTURE TECHNOLOGY TODAY
AMGEN: THE VALUE OF PATENTS
ILLUMINA LAUNCHES A NEW MicroRNA AS....
IS THERE A RATIONAL REASON FOR VERT....
WHY ELAN MUST SOAR?
BIOGEN IDEC (BIIB) FOR SALE
BIIB, PDLI AND GILD
EXELIXIS: SYMPTOMS OF SUCCESS
GENZYME LOOKS GOOD
COLORECTAL CANCER
REGENERON PHARMACEUTICALS (REGN)
SEPTEMBER 2007
ALEMTUZUMAB: FOR M.S. AND OTHER IMP...
A COLLABORATION BETWEEN ARRAY (ARRY)...
DNA METHYLATION ANALYSIS
CORD BLOOD STEM CELL
GENZYME: FDA APPROVES sBLA FOR CAMP....
EXELIXIS ANTI MET INHIBITOR
INVESTING IN PRIVATE BIOTECHS
09/14/2007
AMGEN: THE END OF THE TEMPEST IN TH....
ERBITUX AGAIN
HIV TREATMENT: A NEW MILESTONE
AUGUST 2007
XOMA: A VALIDATING AGREEMENT WITH P..
ONYX (ONXX) AND BAYER (BAY)
NEXAVAR FOR LIVER CANCER
TYSABRI: VERY OPTIMISTIC NEWS
LEFT ALONE
08/13/2007
For Subscribers Only
ILLUMINA (ILMN)
PHARMION'S EXTRAORDINARY NEWS
AMGENS RESPONSE
TRAVELLERS DIARRHEA
JULY 2007
AMGEN'S ANEMIA DRUGS SAGA
TYSABRI FOR CROHN
CRUCELL TECHNOLOGIES, TARGACEPT
AND....
BIOGEN IDEC BEATS ANALYSTS EXPECTAT....
GILEAD AND CUBIST
OPIOID INDUCED CONSTIPATION (OIC)
ANGINA
NANOGEN (NGEN) A FAST HEART TEST
WIDE ROLE OF IL-1 IN DISEASES
A LUCRATIVE PARTNERSHIP
AMGEN AND GENENTECH BEAT CRITICS' ....
DENDREONS TALE STILL ALIVE
HELPING CYSTIC FIBROSIS
PATIENTS
GILD, ALNY AND NWBO:OB?
TYSABRI IS THE BEST
A BREAKTHROUGH FROM
ILLUMINA AND
NEXAVAR
JUNE 2007
COMMENTS ON PDLI, CURAGEN
AND OTHER..
TECHNOLOGIES ON THE ROAD
TO VALIDAT...
AN APPROVAL FOR GILEAD AND
APPROVAL .
OPTIMISTIC NEWS
IL-1 TRAP AND INFLAMMATORY DISEASES
CREATING PERMANENT T-CELL
RESISTANC....
ASCO
NOVAVAX: A MODEL
FLU VACCINE?
MAY 2007
DENDREON (DNDN) AGAIN
ELAN'S ALZHEIMER\'S
DISEASE PROGRA...
GENZ, MEDI, CATS ON A
HOT TIN ROOF
EXELIXIS (EXEL): A TYPICAL PROMISING BIOTECH...
FOREST LABS AND CYPRESS BIOSCIENCE
HIGH-TECH DISCLAIMERS
SATRAPLATIN
PILL FOR PROSTATE CANCER..
VICAL (VICL) AND DNA
VACCINE
2007
FOUR GOOD NEWS FROM PROHOST PORTFOLIO
GENENTECH, ARIAD AND ALNYLAM
GILEAD TO ACQUIRE MYOGEN FOR $2.5 BILLION
AMGEN: APPROVAL OF
VECTIBIX
CRUCELL HAS SEVERAL GOOD NEWS
PHARMION AND GPC BIOTECH: EXCELLENT NEWS
AMYLIN: GOOD NEWS ABOUT DIABETES DRUG
PROHOST DID IT AGAIN
SYNOPSIS
DEAR PROHOST: IS GENTA DEAD?
THE VALUES OF SMALL BIOTECHS
TREATING CHILDREN WIITH BATTEN DISEASE
ISIS CHOLESTEROL DRUG
TODAY'S UPS AND DOWNS
GENTA, GENASENSE AND CLL
NABI:
WHAT THE HEDGE FUND WANTS?
GOOD NEWS FROM FOUR BIOTECHS?
OTHER RECENT
COMMENTS
PROVENGE AGAIN
THE FDA AND PROVENGE
MILLENNIUM QUARTERLY RESULTS
GENETIC ORIGIN OF
DISEASES
TYSABRI
ENDREON\'S PROVENGE: PROMISING NEW....
GENENTECH: UNNECESSARY DEBATE.
02/13/2008 Avastin is already
a blockbuster. Why making a fuss out of its approval for breast cancer?
COMPUGEN: TIME FOR RECOGNITION
02/12/2008 Compugen took
time to build its strong engines. Has time come to reap the fruits.
GIANTS AND DWARFS
02/15/2008 Genentech\'s management
has proven time and time again it is a giant. That\'s why we never lost
faith in this firm\'s unparalleled capability to grow.
deCODE: SNP PROSTATE CA TEST LAUNCH....
02/14/2008 We are at the age of
personalized medicine. deCODE Genetics has launched a swab test that
detects increased risk for prostate cancer. The event marks a new
milestone in the fast evolution of biotechnology.
D
[ Home ] [ Members Area ] [ About Prohost ] [ Impacting News ]
Send mail to
prohost@aol.com with questions or comments about
this web site.
Copyright 2003 Prohost Research, Inc.
|
|
